https://www.selleckchem.com/ALK.html
The development of regenerative therapy for human spinal cord injury (SCI) is dramatically restricted by two main challenges the need for a safe source of functionally active and reproducible neural stem cells and the need of adequate animal models for preclinical testing. Direct reprogramming of somatic cells into neuronal and glial precursors might be a promising solution to the first challenge. The use of non-human primates for preclinical studies exploring new treatment paradigms in SCI results in data with more translational relevance to human
Like
Comment
Share
